Crispr Therapeutics AG (CRSP) — Net Asset Quality Index
Crispr Therapeutics AG (CRSP) has a Net Asset Quality Index of 66.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $2.73 Billion minus total liabilities of $911.26 Million yields net assets of $1.81 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See CRSP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Crispr Therapeutics AG Net Asset Quality Index Over Time (2014–2025)
This chart shows how Crispr Therapeutics AG's Net Asset Quality Index has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the index stands at 66.6%, representing net assets of $1.81 Billion against total assets of $2.73 Billion USD. Explore Crispr Therapeutics AG operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Crispr Therapeutics AG (2014–2025)
The table below presents the year-by-year Net Asset Quality Index for Crispr Therapeutics AG from 2014 to 2025, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Crispr Therapeutics AG market cap and net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.8% | $1.92 Billion | $2.27 Billion | $343.43 Million | ▼ -1.3 pp |
| 2024 | 86.2% | $1.93 Billion | $2.24 Billion | $309.95 Million | ▲ +1.7 pp |
| 2023 | 84.4% | $1.88 Billion | $2.23 Billion | $346.77 Million | ▲ +0.8 pp |
| 2022 | 83.6% | $1.88 Billion | $2.24 Billion | $367.58 Million | ▼ -3.6 pp |
| 2021 | 87.2% | $2.40 Billion | $2.75 Billion | $352.42 Million | ▼ -3.8 pp |
| 2020 | 91.0% | $1.66 Billion | $1.83 Billion | $163.73 Million | ▲ +3.0 pp |
| 2019 | 88.1% | $939.42 Million | $1.07 Billion | $127.33 Million | ▲ +7.9 pp |
| 2018 | 80.2% | $392.19 Million | $489.02 Million | $96.82 Million | ▲ +11.0 pp |
| 2017 | 69.2% | $187.83 Million | $271.35 Million | $83.51 Million | ▲ +1.7 pp |
| 2016 | 67.5% | $232.85 Million | $344.96 Million | $112.12 Million | ▲ +85.8 pp |
| 2015 | -18.3% | $-29.12 Million | $159.42 Million | $188.55 Million | ▲ +438.4 pp |
| 2014 | -456.7% | $-6.97 Million | $1.53 Million | $8.50 Million | — |